Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
It is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed treatment in the United Kingdom at this time
Sanyal, et al.s Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis from June, indicated significant efficacy of the GLP1-RA semaglutide in treating fatty liver disease, where it led to resolution of steatohepatitis without worsening of fibrosis in 63% of treated participants relative to 34% in the placebo group. The second trial demonstrated a dramatic effect of tirzepatide, a dual GIP and GLP-1RA, revealing a 10-fold reduction in the progression from prediabetes to type 2 diabetes, relative to placebo, in individuals with obesity who were treated with tirzepatide, Abel says
Eligibility should begin with members most likely to benefit within a realistic timeframe beyond BMI alone, considering cardiometabolic risk, comorbidities, diabetes status, and the member's full clinical picture
UK-wide licensing for human medicines
US$ 26.22
US$ 20.66
US$ 20.92
US$ 29.85
US$ 22.59
US$ 22.36
